• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neoadjuvant PD-1/PD-L1 inhibitors plus chemotherapy in resectable gastric and gastroesophageal junction cancer.

作者信息

Taherifard Erfan, Saeed Anwaar

机构信息

Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

出版信息

Transl Gastroenterol Hepatol. 2024 Aug 14;9:59. doi: 10.21037/tgh-24-44. eCollection 2024.

DOI:10.21037/tgh-24-44
PMID:39503035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11535811/
Abstract
摘要

相似文献

1
Neoadjuvant PD-1/PD-L1 inhibitors plus chemotherapy in resectable gastric and gastroesophageal junction cancer.新辅助PD-1/PD-L1抑制剂联合化疗用于可切除的胃癌和胃食管交界癌
Transl Gastroenterol Hepatol. 2024 Aug 14;9:59. doi: 10.21037/tgh-24-44. eCollection 2024.
2
Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.新辅助化疗联合PD-1/PD-L1抑制剂治疗局部晚期、可切除的胃或胃食管交界腺癌：一项系统评价和荟萃分析。
Front Oncol. 2023 Jan 26;13:1103320. doi: 10.3389/fonc.2023.1103320. eCollection 2023.
3
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.胃和胃食管结合部腺癌的新辅助阿替利珠单抗联合化疗：Ⅱ期 PANDA 试验。
Nat Med. 2024 Feb;30(2):519-530. doi: 10.1038/s41591-023-02758-x. Epub 2024 Jan 8.
4
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.胃/胃食管结合部可切除癌患者中 durvalumab 联合 FLOT 化疗的 III 期研究（Matterhorn 研究）
Future Oncol. 2022 Jun;18(20):2465-2473. doi: 10.2217/fon-2022-0093. Epub 2022 May 10.
5
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.在新辅助治疗后，胃食管交界处腺癌中程序性细胞死亡蛋白 1（PD-1）和程序性细胞死亡配体 1（PD-L1）的表达发生显著变化。
Eur J Surg Oncol. 2022 Feb;48(2):383-390. doi: 10.1016/j.ejso.2021.08.016. Epub 2021 Aug 11.
6
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.新辅助纳武利尤单抗或纳武利尤单抗联合 LAG-3 抑制剂 relatlimab 治疗可切除食管/胃食管交界处癌：一项 Ib 期试验和 ctDNA 分析。
Nat Med. 2024 Apr;30(4):1023-1034. doi: 10.1038/s41591-024-02877-z. Epub 2024 Mar 19.
7
Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.一线 PD-1 抑制剂联合化疗治疗低 PD-L1 表达的胃或胃食管结合部腺癌患者的临床结局和生物标志物探索。
Cancer Immunol Immunother. 2024 Jun 4;73(8):144. doi: 10.1007/s00262-024-03721-6.
8
Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.新辅助 PD-(L)1 阻断联合铂类化疗治疗潜在可切除的驱动基因阳性非小细胞肺癌。
World J Surg Oncol. 2024 Jun 18;22(1):159. doi: 10.1186/s12957-024-03434-1.
9
Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.新辅助-辅助与新辅助单药 PD-1/PD-L1 抑制剂治疗可切除 NSCLC 患者的疗效比较：一项间接荟萃分析。
JAMA Netw Open. 2024 Mar 4;7(3):e241285. doi: 10.1001/jamanetworkopen.2024.1285.
10
Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.抗PD-1/PD-L1药物与化疗在胃癌或胃食管交界癌患者中的疗效和安全性：一项系统评价和荟萃分析。
Medicine (Baltimore). 2019 Nov;98(47):e18054. doi: 10.1097/MD.0000000000018054.

本文引用的文献

1
Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.新辅助免疫疗法改善可切除胃食管交界癌的预后：系统评价和荟萃分析。
Cancer Med. 2024 May;13(9):e7176. doi: 10.1002/cam4.7176.
2
Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma.局部晚期胃癌或胃食管交界腺癌的新辅助化疗免疫疗法
Front Oncol. 2024 Apr 15;14:1342162. doi: 10.3389/fonc.2024.1342162. eCollection 2024.
3
Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
可切除胃/胃食管交界肿瘤新辅助免疫治疗的评价：荟萃分析和系统评价。
Front Immunol. 2024 Jan 30;15:1339757. doi: 10.3389/fimmu.2024.1339757. eCollection 2024.
4
Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer.早期免疫重塑指导晚期胃癌一线化疗免疫治疗的临床应答。
Cancer Discov. 2024 May 1;14(5):766-785. doi: 10.1158/2159-8290.CD-23-0857.
5
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.胃和胃食管结合部腺癌的新辅助阿替利珠单抗联合化疗：Ⅱ期 PANDA 试验。
Nat Med. 2024 Feb;30(2):519-530. doi: 10.1038/s41591-023-02758-x. Epub 2024 Jan 8.
6
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.新辅助和辅助帕博利珠单抗联合化疗治疗局部晚期胃或胃食管交界癌（KEYNOTE-585）：多中心、双盲、随机 3 期研究的中期分析。
Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19.
7
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.可切除食管胃结合部腺癌患者围手术期使用阿替利珠单抗联合氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛治疗的随机、多中心、Ⅱ/Ⅲ期 DANTE/IKF-s633 试验的中期结果。
J Clin Oncol. 2024 Feb 1;42(4):410-420. doi: 10.1200/JCO.23.00975. Epub 2023 Nov 14.
8
Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm.错配修复缺陷/微卫星高度不稳定的胃肠道癌患者的新辅助免疫治疗：一种不断变化的模式
Cancers (Basel). 2023 Jul 28;15(15):3833. doi: 10.3390/cancers15153833.
9
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.晚期胃食管癌的免疫治疗与靶向治疗：美国临床肿瘤学会指南
J Clin Oncol. 2023 Mar 1;41(7):1470-1491. doi: 10.1200/JCO.22.02331. Epub 2023 Jan 5.
10
Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.局部进展期胃癌的免疫检查点阻断、抗血管生成和化疗的新辅助治疗。
Nat Commun. 2023 Jan 3;14(1):8. doi: 10.1038/s41467-022-35431-x.